Skip to main content
Ovoca Bio Plc logo

Ovoca Bio Plc — Investor Relations & Filings

Ticker · OVXA ISIN · IE00B4XVDC01 LEI · 213800ST2AK5XQ1O5207 IR Manufacturing
Open in API
Filings indexed 99 across all filing types
Latest filing 2020-08-14 Regulatory Filings
Country IE Ireland
Listing IR OVXA

About Ovoca Bio Plc

https://ovocabio.com/

Ovoca Bio is a clinical-stage biopharmaceutical company focused on developing novel treatments for women's health. Its lead product candidate is Orenetide, a treatment for premenopausal women with hypoactive sexual desire disorder (HSDD), a condition characterized by a distressing lack of sexual desire and representing a significant area of high unmet medical need. The company is advancing Orenetide through clinical development for major global markets and has filed for marketing approval in the US and Europe. Ovoca Bio's strategy includes leveraging its patent portfolio and considering licensing or collaboration opportunities to accelerate the availability of its product candidates to patients.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is very short (1356 characters) and is explicitly labeled as an 'RNS Number'. It announces a 'Price Monitoring Extension' related to trading procedures on the London Stock Exchange, which is a general regulatory announcement concerning market operations rather than a specific financial report (like 10-K, IR, or ER). Since it is a general regulatory announcement that doesn't fit the other specific categories (like DIRS, DIV, or MANG), the most appropriate classification is the general regulatory filing fallback category.
2020-08-14 English
Annual Report
Report Publication Announcement Classification · 100% confidence The document explicitly states its purpose in the headline: "Publication of 2019 Annual Report". It details the financial year ended 31 December 2019 and includes a 'Letter from the CEO' and '2019 Highlights', which are characteristic components of an Annual Report. Although it is distributed via RNS (Regulatory News Service), the core content is the Annual Report itself, not just an announcement of its publication (which would typically be shorter and focus only on the release). Since the document text is substantial (7784 chars) and contains the substance of the report's summary/letter, it is classified as the Annual Report (10-K equivalent for non-US filers, or simply the comprehensive annual filing). Given the options, 10-K is the closest standard for a full annual report, but since the document is clearly announcing and summarizing the Annual Report, and the definition for 10-K is 'Official yearly report covering company activity and full financial performance', this fits best. However, the document is titled 'Publication of 2019 Annual Report' and is distributed via RNS. If the document were purely the announcement, RPA would be chosen. Since it contains the CEO letter and highlights, it leans towards the report content. Given the context of a non-US company publishing an 'Annual Report and Financial Statements', and the existence of a specific '10-K' code for Annual Reports, I will select 10-K as the closest fit for the comprehensive annual filing content being summarized, despite the RNS distribution.
2020-06-26 English
Second Price Monitoring Extn
Regulatory Filings Classification · 99% confidence The document is very short (1372 characters) and is explicitly labeled as an 'RNS Number'. The content describes a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange, which is a specific, non-standard regulatory market announcement. Since it is a general regulatory announcement that doesn't fit the specific categories like DIV, DIRS, or ER, and it is not announcing the publication of a major report (like 10-K or IR), the most appropriate classification is the general regulatory filing fallback category.
2020-04-14 English
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1355 characters) and begins with an 'RNS Number' and is dated April 14, 2020. The content describes a 'Price Monitoring Extension' for an auction call period, which is a specific operational announcement related to trading on the London Stock Exchange. It explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' Since this is a general regulatory announcement that doesn't fit into specific financial reporting categories (like 10-K, ER, or DIV), and it is clearly an RNS communication, the most appropriate classification is Regulatory Filings (RNS). It is not an announcement of a report (RPA) but a direct regulatory update.
2020-04-14 English
Acquisition of Remaining Minority Interest in IVIX
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated March 24, 2020. The content details a corporate action: the 'Acquisition of Remaining Minority Shareholding in IVIX LLC'. This is a significant corporate event announcement, not a periodic financial report (like 10-K or IR) or a general presentation (like IP or AGM-R). Since it involves a material transaction (acquisition of a subsidiary stake) and is disseminated via the RNS system, it falls under the category of a significant corporate announcement. While it relates to capital structure changes, the primary focus is the transaction itself. Given the options, this type of material, non-standardized corporate news release, especially one originating from the RNS system, is best classified as a general Regulatory Filing (RNS), as it doesn't perfectly match the more specific categories like CAP (Financing Update) or TAR (M&A Activity, which usually implies a takeover bid or merger proposal). However, since it is a specific corporate transaction announcement, and RNS is the fallback, I will check if it fits better elsewhere. It is not a Director's Dealing (DIRS), Dividend (DIV), or Share Issue (SHA/POS). It is a material corporate event announcement disseminated through the regulatory news service. RNS is the most appropriate fallback for specific, non-periodic corporate news that isn't covered by the other specific codes.
2020-03-24 English
Attendance at Bio-Europe Conference
Regulatory Filings Classification · 99% confidence The document is very short (2508 characters) and announces that the company management will be attending and hosting meetings at the BIO-Europe Partnering Conference. It is a brief update regarding company activity and investor engagement, not a full financial report (like 10-K or IR) or a specific regulatory filing like a Director's Dealing or Dividend Notice. It is distributed via RNS (Regulatory News Service), which suggests it is a general regulatory announcement. Since it doesn't fit the specific categories like ER, IP, or CT, and it's a general corporate update distributed through the official news service, the most appropriate fallback is Regulatory Filings (RNS), although it could also be argued as a very light Investor Presentation (IP) or Management Update (MDA). Given the format and the explicit mention of RNS as the provider, RNS is the safest classification for a general, non-financial-result-focused announcement.
2019-11-07 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.